Date | Price Target | Rating | Analyst |
---|---|---|---|
6/24/2021 | $5.00 | Buy | Aegis Capital |
SC 13G - Can-Fite BioPharma Ltd. (0001536196) (Subject)
SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)
SC 13G/A - Can-Fite BioPharma Ltd. (0001536196) (Subject)
6-K - Can-Fite BioPharma Ltd. (0001536196) (Filer)
EFFECT - Can-Fite BioPharma Ltd. (0001536196) (Filer)
424B3 - Can-Fite BioPharma Ltd. (0001536196) (Filer)
ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE:OSTX) and Can-Fite BioPharma Ltd. (NYSE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:OS Therapies: https://www.redchip.com/assets/access/ostx_accessCan-Fite: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate
ORLANDO, FL / ACCESSWIRE / May 10, 2024 / RedChip Companies will air interviews with Can-Fite BioPharma Ltd. (NYSE:CANF) and Nutriband Inc. (NASDAQ:NTRB) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, May 11, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:Can-Fite: https://www.redchip.com/assets/access/canf_accessNutriband: https://www.redchip.com/assets/access/ntrb_accessIn an exclusive interview, Pnina Fishman, Executive Chairperson and Chief Scientific Officer of Can-Fite BioPharma, appears on the RedChip Small Stocks, Big Money™ show on Blo
Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the year ended December 31, 2022. 2022 & Recent Corporate and Clinical Development Highlights Include: PICLIDENOSON Phase III COMFORT™ Psoriasis Trial Met Primary Endpoint – Patients receiving Piclidenoson 3mg demonstrated a statistically significant improvement when compared with placebo, as measured by the Psoriasis Area and Severity Index (PASI) 75 response at week 16 of treatment. An excellent safety profile was recorded. Pivotal Phase III Psoriasis Registration P
Aegis Capital initiated coverage of Can Fite Biofarma with a rating of Buy and set a new price target of $5.00
Study will aim to establish safety and clinical efficacy PETACH TIKVA, Israel, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it received approval from the Israeli Ministry of Health (MoH) to conduct Phase IIa clinical trial with orally-administered Namodenoson in the treatment of pancreatic carcinoma. "We are very much encouraged by the excellent data in the pre-clinical studies demonstrating the impressive anti-cancer effect of namodenoson and definitive molecular mechanism of action against
RAMAT GAN, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE:CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for H1 2024. H1 2024 Highlights Exercise of Warrants for Approximately $5.0 Million in Gross Proceeds – in August, the Company announced the exercise of certain outstanding warrants to purchase up to an aggregate of 2,857,143 American Depositary Shares (ADSs), having an exercise price of $1.75 per ADS, issued by Can-Fite in January 2023 and November 2023. In consideration for the immediate exercise of
ORLANDO, FL / ACCESSWIRE / August 9, 2024 / RedChip Companies will air interviews with OS Therapies Inc. (NYSE:OSTX) and Can-Fite BioPharma Ltd. (NYSE:CANF) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, August 10, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.Access the interviews in their entirety at:OS Therapies: https://www.redchip.com/assets/access/ostx_accessCan-Fite: https://www.redchip.com/assets/access/canf_accessIn an exclusive interview, Paul Romness, Chairman and CEO of OS Therapies, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to provide a corporate
EF Hutton analyst Jason Kolbert initiates coverage on Can Fite Biofarma (AMEX:CANF) with a Buy rating and announces Price Target of $10.
Can-Fite plans to start shortly a Phase IIa clinical study that will be a multicenter open-label trial in patients with advanced pancreatic adenocarcinoma whose disease has progressed on at least first line therapy. The trial will evaluate the safety, clinical activity, and pharmacokinetics (PK) of Namodenoson in this population. Can-Fite has already been granted Orphan Drug Status for Namodenoson for the indication of advanced liver cancer by the FDA and also by the EMA.
This Drug Candidate Is Currently Used In A Pivotal Phase 3 Study For Patients With Advanced Liver Cancer And A Phase 2b Study For Mash (Metabolic Dysfunction-associated Steatohepatitis)